Axsome Therapeutics (AXSM) Intangibles (2022 - 2026)

Axsome Therapeutics has reported Intangibles for 5 years, with the latest figure at $38.9 million in Q1 2026.

• Quarterly Intangibles fell 14.07% year-over-year to $38.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.9 million (down 14.07% YoY) and the FY2025 annual result came in at $63.8 million, up 36.05% from the prior year.
• Intangibles slipped to $38.9 million in Q1 2026 per AXSM's latest filing, from $63.8 million in the prior quarter.
• Over five years, Intangibles peaked at $63.8 million in Q2 2022 and troughed at $38.9 million in Q1 2026.
• A 5-year average of $55.2 million and a median of $57.3 million in 2023 frame the typical range for Intangibles.
• The widest YoY moves for Intangibles: up 36.05% in 2025, down 33.97% in 2025.
• Over 5 years, Intangibles stood at $63.8 million in 2022, then changed by 0.0% to $63.8 million in 2023, then retreated by 26.5% to $46.9 million in 2024, then surged by 36.05% to $63.8 million in 2025, then tumbled by 38.95% to $38.9 million in 2026.
• According to Business Quant data, Intangibles over the past three periods registered $38.9 million, $63.8 million, and $42.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.